Five myeloma proteins of the Ge group, three of which are shown in Table 1, were negative for all the Gm characters. These myeloma proteins were found to show a unique fast mobility for the F component produced by papain splitting not found with other myeloma proteins2. This suggests a considerable degree of individuality for this class of protein although they still cross-reacted in the F fragments with myeloma proteins of the other groups.

In addition to the Ge group, the Gm(b-) members of the Vi group, and the rare member of the We group, a number of other myeloma proteins were encountered which were also (a-b-f). Two of these are shown at the bottom of Table 1. Most antisera showed these myelomas to be deficient but as vet no antiserum has been obtained which recognizes them in a positive fashion. Evidence also was obtained indicating that this was not a homogeneous group but consisted of a mixture of types.

Experiments on the distribution of the various groups among the molecules of normal  $\gamma$ -globulin indicate that they in general parallel the incidence among myeloma proteins. Quantitative precipitin analysis on twenty normal sera indicates a range for the Vi type protein from 0.1 to 1.1 mg/c.c. (ref. 2). A counterpart for the Ge group was also found and this occurred at a lower level. All sera examined, including those from whites of different Gm phenotype, negroes, Chinese and American Indians contained the Vi, We and Ge type proteins.

It has been thought in the past that genes Gm<sup>a</sup> and Gm<sup>b</sup> are alleles in Caucasians<sup>10</sup>. Certain unusual features, however, have been encountered in other racial groups<sup>13,14</sup>. The results presented here showed that types  $\operatorname{Gm}(a+)$  and  $\operatorname{Gm}(b+)$  did not occur in the same group of 75  $\gamma$ -globulins. All Gm(a+) and Gm(f+) myeloma proteins fell into the We group which, furthermore, did not include any Gm(b+) proteins. It is known that the distribution of Gm(b) and of Gm(f) is very similar in Caucasians, because white individuals are, with rare excep-tions, positive for both or for neither<sup>8,9</sup>. Combining these results, it seems possible that  $Gm^{f}$  (certainly not  $Gm^{b}$ ) may be the true allele of Gm<sup>a</sup>. It is then a reasonable concept that the 'We locus' (with  $Gm^{a}$  and possibly  $Gm^{f}$  as major alleles) and the 'Vi locus' (with  $Gm^{b}$  and at least one unknown allele) are closely linked. Reasoning along these lines leads to the prediction that Gm(b- $\gamma$ -globulins of the Vi group contain the product of the true allele(s) of Gm<sup>b</sup> and that genes at a third locus, the 'Ge locus', as well as other loci, determine characteristics of the H chains of other 7S  $\gamma$ -globulin molecules.

We thank Dr. R. Bachmann, Dr. C.-B. Laurell and Dr. U. Nilsson, of the Department of Clinical Chemistry, Malmö General Hospital, for certain of the myeloma sera and myeloma fractions.

HENRY G. KUNKEL JAMES C. ALLEN HOWARD M. GREY

The Rockefeller Institute, New York.

LARS MARTENSSON RUNE GRUBB

Institute of Bacteriology, Lund, Sweden.

<sup>1</sup> Grey, H. M., and Kunkel, H. G., Fed. Proc., 23, 454 (1964).

- <sup>a</sup> Grey, H. M., and Kunkel, H. G., *J. Exp. Med.*, **120**, 253 (1964). <sup>a</sup> Terry, W. D., and Fahey, J. L., *Fed. Proc.*, **23**, 454 (1964).
- <sup>4</sup> Harboe, M., Osterland, C. K., and Kunkel, H. G., Science, 136, 979 (1962).
- <sup>5</sup> Franklin, E. C., Fudenberg, H., Meltzer, M., and Stanworth, D. R., Proc. U.S. Nat. Acad. Sci., 48, 914 (1962).

- <sup>6</sup> Mårtensson, L., Acta Med. Scand., Supp. 367, 87 (1961).
   <sup>7</sup> Harboe, M., Osterland, C. K., Mannik, M., and Kunkel, H. G., J. Exp. Med., 116, 719 (1962). <sup>8</sup> Gold, E. R., Mårtensson, L., and Ropartz, C., Vox. Sang. (in the press).
- <sup>9</sup> Mårtensson, L. (to be published).
- 1º Harboe, M., Acta Path. et Microbiol. Scand., 47, 191 (1959).
- <sup>11</sup> Franklin, E. C., Meltzer, M., Guggenheim, F., and Lowenstein, J., Fed. Proc., 22, 264 (1963).
- 13 Osserman, E. F., and Takatsuki, K., Medicine, 42, 357 (1963).
- <sup>13</sup> Steinberg, A. G., and Wilson, J. A., Amer. J. Human Genetics, 15, 96 (1963).
- <sup>14</sup> Ropartz, C., Rivat, L., and Rousseau, P. Y., Vox Sang., 8, 717 (1963).

## PHARMACOLOGY

## Transfer of Oxytocin from the Maternal to the Foetal Circulation in the Ewe

LITTLE is known of the transfer of peptides between the maternal and fœtal circulation. In their exhaustive review, Hagermann and Villec<sup>1</sup> mention the results of the work of Krzysztoporski<sup>2</sup>, who showed that simple peptides cross the placental barrier, and those of Knobil and Josimovitch<sup>3</sup> that insulin crosses the mono-layered placenta of the rat. Other information on the placental penetration of peptide hormones is sparse and contradictory. High concentrations of oxytocin in maternal blood during parturition have been reported<sup>4</sup> and it seemed therefore of interest to investigate the possibility that oxytocin in the maternal circulation might reach the fœtus.

		C ACTIVITY							
INJE	CTION OF	OXYTOCIN	INTO	) THE	MATE	RNAL U	JTERINE	ARTERY	r.

Ewe	Days before	Dose of	Interval between oxytocin injection		vity of plasma v/ml. blood
No.	full	oxytocin	and starting col-		After
	term	(units)	lection of blood sample (seconds)	Control	oxytocin injection
1	25	40	10	$3 \cdot 0$	3.0
2	17	40	90	$2 \cdot 3$	3.4
3	17	40	90	3.3	6.0
4	16	20	90	1.2	2.7

The experiments were carried out in pregnant ewes of the Welsh breed, in which the dates of conception were known. The ovine placenta is cotyledonary and has five layers, the fœtal and maternal circulations coming into juxtaposition in the cotyledons. About 20 days before term, the lamb or lambs were removed from the uterus by Caesarian section under spinal nerve block anæsthesia with the umbilical cord intact. (The operations were kindly carried out by Prof. Messervy and his staff.) Control samples of about 20 ml. of blood were withdrawn from the umbilical artery into heparinized syringes. Oxytocin (20-40 units 'Syntocinon', Sandoz) was injected into the uterine artery of the ewe, and a second sample of arterial blood withdrawn from the cord either before or after the oxytocin-induced contraction of the uterus. After centrifugation at  $0^{\circ}$  C the plasma was separated and extracted by treatment with acetone and ether according to the method of Ginsburg and Smith<sup>5</sup>. Oxytocic activity in the extracts was assayed on the superfused rat uterus<sup>6</sup> using 'Syntocinon' as standard. The results are shown in Table 1. Oxytocic activities equivalent to 1.2-3.3 mu oxytocin/ml. were found in control plasmas. In one experiment the second sample of umbilical arterial blood was collected 10 sec after the injection of oxytocin and before the uterus contracted; there was no difference in the oxytocic activity of the plasma before and after injection. In the remaining three experiments, in which the second samples were collected 90 sec after oxytocin injection when the uterine contraction was apparently maximal, the oxytocic activity of the second plasmas was 50-125 per cent greater than that of the controls. Treatment of the extract of the second sample of plasma in experiment 3 with thioglycollate<sup>7</sup> reduced the oxytocic activity from 6 mu/ml. to 3 mu/ml. blood, that is, to the level found in the control sample. It seems likely that the oxytocic activity in the control sample was due to the presence of kinins in the extract<sup>8</sup> but that the additional activity after injection was due to oxytocin, suggesting that the placental barrier is not impermeable to oxytocin. B. A. NODDLE

Department of Pharmacology,

- University of Bristol.

University of Diffstol.
<sup>1</sup> Hagermann, D. D., and Villee, V. A., Physiol. Rev., 40, 313 (1960).
<sup>2</sup> Krzysztoporski, S., Ginek. pol., 20, 484 (1949).
<sup>8</sup> Knobil, E., and Josimovitch, J. B., Ann. N.Y. Acad. Sci., 75, 895 (1959).
<sup>4</sup> Fitzpatrick, R. J., and Walmsley, C. F., J. Physiol., 163, 13P (1962).
<sup>5</sup> Ginsburg, M., and Smith, M. W., Brit. J. Pharmacol., 14, 327 (1959).
<sup>6</sup> Gaddum, J. H., Brit. J. Pharmacol., 8, 321 (1953).
<sup>7</sup> Vogt, M., Brit. J. Pharmacol., 8, 193 (1953).
<sup>8</sup> Bisset, G. W., in Oxytocin, edit. by Caldeyro, Barcia and Heller (Pergamon Press: Oxford, 1959).